March 16, 2020 / 12:57 PM / in 14 days

BRIEF-Arcutis Announces Inclusion Of Children In On-Going Pivotal Phase 3 Clinical Trials Evaluating Topical Roflumilast

March 16 (Reuters) - Arcutis Biotherapeutics Inc:

* ARCUTIS ANNOUNCES INCLUSION OF CHILDREN IN ON-GOING PIVOTAL PHASE 3 CLINICAL TRIALS EVALUATING TOPICAL ROFLUMILAST (ARQ-151) AS A POTENTIAL ONCE DAILY TOPICAL TREATMENT FOR PLAQUE PSORIASIS

* ARCUTIS BIOTHERAPEUTICS- PHASE 3 TRIALS FOR TOPICAL ROFLUMILAST (ARQ-151) TOPLINE DATA ANTICIPATED FIRST HALF 2021 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below